CA-DENODO
21.3.2022 09:02:09 CET | Business Wire | Press release
Denodo , the leader in data management, today announced that its subscription license revenue grew more than 50 percent year-over-year, as the company moved close to becoming a 100 percent subscription-based revenue business. While new customer acquisitions and existing customer expansion remained strong and steady year-over-year, Denodo’s cloud marketplace presence encountered the fastest growth with more than 300 transactions in 2021.
Denodo customers’ positive sentiment about its product, services, and support was once again captured as part of the Gartner Peer Insights reviews and, as a result, Denodo has again been recognized as a Customer's Choice in the Gartner Peer Insights “Voice of the Customer”: Data Integration Tools , 28 January 2022. With an overall rating of 4.4 out of 5, Denodo is one of the only three Gartner® Magic Quadrant™ for Data Integration Tools Leaders to receive Customers’ Choice for 2022 and is the third highest rated data integration vendor in the report. Denodo was also positioned as a Leader for the Second Consecutive Year in the 2021 Gartner® Magic Quadrant™ for Data Integration Tools . During the same year, Denodo customers and Denodo Platform were bestowed with numerous awards and recognitions, such as TDWI Best Practices Award, Ventana Research Digital Leadership Award, and DBTA Readers' Choice Awards, to name a few.
During 2021, Denodo added important brand names to its already stellar global customer roster, including Credit Suisse, Deutsche Bank, Toyota Financial Services, Johnson & Johnson, and Goldwind. During the same period, Denodo Platform version 8, which was launched in 2020 to offer enterprises the ability to deploy enterprise grade logical data fabric, added some major capabilities including AI & Recommendations and Advanced Semantics. These new additions help enterprise data and analytics teams automate frequently used data management functions, improve collaboration between data stewards and business users, and secure data access.
The Company extended its worldwide footprint to 25 offices spanning 20 countries, including new offices in South Korea, Sweden, Netherlands and Belgium. During the same year, strategic technology and consulting alliances also intensified as marked by a 56 percent increase in new signed partner agreements and significant growth within current partnerships, bringing a 192 percent increase in revenue from this important channel.
“Every company rooted in making data-driven business decisions is realizing that it is impractical to move all their data in a single repository such as a cloud data lake or cloud data warehouse,” said Angel Viña, founder and CEO of Denodo. “That is exactly why they selected Denodo Platform to build their logical data fabric to integrate, manage and deliver their enterprise data to business stakeholders. We thank our partners and customers alike for their continued support for our platform and we are looking forward to helping hundreds of new customers who are looking to make insights-driven business decisions and support their enterprise data across cloud and regional boundaries.”
Please Tweet: #dataintegration leader @denodo announces double-digit revenue growth and strong momentum in customer acquisition through #amazon #google and #azure marketplaces
About Denodo
Denodo is a leader in data management. The award-winning Denodo Platform is the leading data integration, management, and delivery platform using logical approach to enable self-service BI, advanced analytics, hybrid/multi-cloud integration, and enterprise data services. Realizing more than 400% ROI and millions of dollars in benefits, Denodo’s customers across large enterprise and mid-market companies in 30+ industries have received payback in less than 6 months. For more information, visit www.denodo.com or call +1 877 556 2531 / +44 (0) 20 7869 8053.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220321005256/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom